The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2019

Filed:

Aug. 04, 2017
Applicant:

Bristol-myers Squibb Company, Princeton, NJ (US);

Inventors:

Robert James Peach, San Diego, CA (US);

Joseph Naemura, Bellevue, WA (US);

Peter S. Linsley, Seattle, WA (US);

Jurgen Bajorath, Bonn, DE;

Assignee:

BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); A61K 38/17 (2006.01); C07K 14/725 (2006.01); C07H 21/04 (2006.01); C12N 5/0783 (2010.01); A61K 39/395 (2006.01); A61K 39/39 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 38/1774 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); C07H 21/04 (2013.01); C07K 14/70521 (2013.01); C12N 5/0636 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01); C12N 2501/51 (2013.01);
Abstract

The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.


Find Patent Forward Citations

Loading…